GBA Presents: House of Gummy-!

stonedinvestor · Feb 5, 2024

stonedinvestor said:
Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)
PR Newswire
Wed, January 17, 2024, 7:00 AM EST·6 min read
In this article:
ADAG
-43.6842%
Watchlist

Pattern
Bullish

- Data from first tranche of MSS CRC patients treated with ADG126 10 mg/kg every three weeks (Q3W) in dose expansion showed clinical benefit including confirmed responses at higher, more frequent and repeat doses of the anti-CTLA-4 therapy -

- Preliminary survival analysis of ADG126 10 mg/kg dosing regimens in patients without liver and peritoneal metastases indicates best-in-class median progression-free survival (PFS) of seven months -

- Data from additional patients at 10 mg/kg Q3W dosing regimen expected throughout 2024 -

SAN DIEGO and SUZHOU, China, Jan. 17, 2024 /PRNewswire/ -- Adagene Inc. ("Adagene") (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced data from its presentation at the American Society of Clinical Oncology (ASCO) 2024 Gastrointestinal (GI) Cancers Symposium, taking place January 18-20 in San Francisco.

"The expanded therapeutic index for the masked ADG126 allows us to dose with a higher and more frequent effective dose of anti-CTLA-4 therapy than today's options," said Daneng Li, MD and Associate Professor Department of Medical Oncology & Therapeutics Research at the City of Hope Comprehensive Cancer Center. "These promising data support further evaluation of this potential best-in-class anti-CTLA-4 antibody, ADG126, in combination with pembrolizumab for MSS CRC patients, including battling new liver lesions in those patients initially without detectable liver metastasis. We also see a tremendous opportunity to help patients in other tumor types where there is a significant need for safe and potent anti-CTLA-4 therapy."

Key highlights from the poster (November 30, 2023 data cutoff) include:

Results from dose escalation and dose expansion cohorts of ADG126 in combination with Merck & Co., Inc., Rahway, NJ, USA's anti-PD-1 therapy KEYTRUDA® (pembrolizumab) (200 mg/Q3W) demonstrated a best-in-class safety profile for ADG126 at doses from 6 mg/kg to 10 mg/kg in heavily pre-treated advanced/metastatic patients (N=46):

- Limited dose-dependent toxicities were observed.
- Grade 3 TRAEs occurred in 5/46 patients (10.8%), with no Grade 4 or 5 TRAEs and a discontinuation rate of 6.5% (3/46).

In dose escalation across tumor types, two partial confirmed responses (PRs) were observed among the three patients treated with ADG126 10 mg/kg Q3W, which triggered expansion cohorts at this dosing regimen. One of the patients had PD-1 refractory cervical cancer and the other had endometrial cancer. Both confirmed PRs are sustained after more than 55 weeks (over 14 cycles) of treatment.

In dose expansion of patients with MSS CRC, 12 evaluable patients without liver metastases were treated at the active, potent dose of 10 mg/kg Q3W:

- Two confirmed PRs were observed in nine of these patients without peritoneal and liver metastases, resulting in an overall response rate of 22% in this subset.
- An additional seven of these nine patients experienced stable disease (SD) for an overall disease control rate 100% (2 PRs and 7 SD).
- Observation of these clinical activities triggered further expansion into Stage 2 of the Simon's 2-stage design for this dose level, which is currently ongoing with data anticipated throughout 2024.

In a preliminary PFS analysis of those MSS CRC patients free of liver and peritoneal metastasis, a median PFS of seven months was observed in those treated with ADG126 10 mg/kg at two dosing frequencies pooled together [every three weeks (n=9) and every six weeks (n=6)]. The durable clinical activity of ADG126 in combination with pembrolizumab will continue to be evaluated as a larger cohort of subjects becomes evaluable at the 10 mg/kg Q3W dose level.

Commenting on the results, Heinz Josef-Lenz, MD, FACP, Associate Director for Clinical Research and Co-leader of the Translational Science Program at the USC Norris Comprehensive Cancer Center (NCCC) said, "I believe that CTLA-4 is an essential part of an effective immunotherapy for MSS CRC, yet physicians have been limited by the safety challenges from first generation options. The clinical profile of ADG126 in combination with pembrolizumab presents a great opportunity for MSS CRC patients that otherwise have limited immunotherapy options available."

ASCO-GI Poster Presentation Details

Title: Results of a phase 1b/2 study of ADG126 (a masked anti-CTLA-4 SAFEbody) in combo with pembrolizumab (Pembro) in patients (Pts) with metastatic microsatellite-stable (MSS) colorectal cancer (CRC)

Date: Saturday, January 20

Time: 6:30 a.m. – 7:55 a.m. Pacific Time

Onsite Location: Moscone West

Abstract Number: 127

Poster Board: H12

More...

You remember my air in the tire story... learn from it.

Why did I not play this name? cause' I had another similar story with a different bio-- bad excuse...

GBA: JUST KEEP GOING!!!!

stonedinvestor · Feb 5, 2024

HELL YEA!

stonedinvestor · Feb 5, 2024

SHE'S A little crazy... a bit Sharon Stone on E but man this song is great and Miley looks fantastic.

stonedinvestor · Feb 5, 2024

GitLab price target raised by $15 at DA Davidson, » 09:22 GTLB

stonedinvestor · Feb 5, 2024

stonedinvestor said:
$189--$214 I have to fix this and get back in.

MNDY monday.com Ltd.

$214.06 +2.94(+1.39%)4:00 PM 02/02/24
More...

UPDATE--$ 208

JPMorgan SMid Cap software analyst to hold analyst/industry conference call » 10:36 MNDY

stonedinvestor · Feb 5, 2024

Estee Lauder sees returning to organic sales growth in mainland China in 2H » 09:51 EL

stonedinvestor · Feb 5, 2024

stonedinvestor said:
Hate to say it.. but our friend WRAP is back and looks ready to play.
Decent vol today 900K.

Wrap Technologies, Inc. (WRAP)
NasdaqCM - NasdaqCM Real Time Price.
3.7900+0.2900 (+8.29%)
At close: 04:00PM EST
More...

UPDATE-STONEY ON FIRE!

Wrap Technologies, Inc. (WRAP)
NasdaqCM - NasdaqCM Real Time Price.
4.5400+0.4600 (+11.27%)<-------------------------
As of 11:26AM EST.

TrailerParkTed · Feb 5, 2024

stonedinvestor said:
SHE'S A little crazy... a bit Sharon Stone on E but man this song is great and Miley looks fantastic.

More...

Remember when Sinead O’ Conner tried to talk Miley out of flashing her body?

stonedinvestor · Feb 5, 2024

UP MARKET/ DOWN MARKET IT DON'T MATTER WHEN YOU ARE ROLLING WITH GBA!!!!

stonedinvestor · Feb 5, 2024

TrailerParkTed said:
Remember when Sinead O’ Conner tried to talk Miley out of flashing her body?
More...

I GOT TO SAY SHE'S A LITTLE SKINNY BUT OH DEAR MILEY TURNS ME ON..... I MEAN YOU JUST KNOW ONE OF US IS FANTASTIC IN BED....